The European Commission said on Monday it had launched legal action against AstraZeneca for not respecting its contract for the supply of COVID-19 vaccines and for not having a "reliable" plan to ensure timely deliveries.
AstraZeneca said in response that the legal action by the EU was without merit and pledged to defend itself strongly in court.
Under the contract, the Anglo-Swedish company had committed to making its "best reasonable efforts" to deliver 180 million vaccine doses to the EU in the second quarter of this year, for a total of 300 million in the period from December to June.
But AstraZeneca said in a statement on March 12 it would aim to deliver only one-third of that by the end of June, of which about 70 million would be in the second quarter. A week after that, the Commission sent a legal letter to the company in the first step of a formal procedure to resolve disputes.
AstraZeneca's delays have contributed towards hampering the bloc's vaccination drive, as the vaccine developed by Oxford University was initially supposed to be the main one in an EU rollout in the first half of this year. After repeated cuts in supplies, the bloc changed its plans and now relies mostly on the Pfizer-BioNTech vaccine.
"The Commission has started last Friday a legal action against AstraZeneca," the EU spokesman told a news conference, noting all 27 EU states backed the move.
"Some terms of the contract have not been respected and the company has not been in a position to come up with a reliable strategy to ensure timely delivery of doses," the spokesman said, explaining what triggered the move.
"AstraZeneca has fully complied with the Advance Purchase Agreement with the European Commission and will strongly defend itself in court. We believe any litigation is without merit and we welcome this opportunity to resolve this dispute as soon as possible," AstraZeneca said.
Under the contract, the case will need to be resolved by Belgian courts.
"We want to make sure there is a speedy delivery of a sufficient number of doses that European citizens are entitled to and which have been promised on the basis of the contract," the spokesman said.
'WE HAD TO SEND A MESSAGE'
EU officials confirmed the purpose of the legal action was to ensure more supplies than what the company has said it would aim to deliver.
The move follows months of rows with the company over supply issues and amid concerns over the efficacy and safety of the vaccine. Still, while the shot has been linked to very rare cases of blood clots, the EU drugs regulator has recommended its use to contain the spread of COVID-19.
"We had to send a message to (Pascal) Soriot," an EU official said, referring to AstraZeneca's chief executive.
Germany, France and Hungary were among EU states that were initially reticent to sue the company, mostly on the grounds that the move might not speed up deliveries, diplomats said, but eventually they supported it.
After the announcement of the legal action, AstraZeneca said it was in the process of delivering nearly 50 million doses by the end of April, a goal which is in line with the revised-down target of supplying only 100 million shots by the end of the quarter.
The EU wants AstraZeneca to deliver as many as possible of the promised 300 million doses, but would settle for 130 million shots by the end of June, one EU source familiar with the discussions told Reuters, adding the EU had launched an urgent legal procedure and was invoking financial penalties in case of non-compliance.
In a further sign of its irritation towards the company, it has already forgone another 100 million shots that it had an option to buy under the contract signed in August.
The spat with AstraZeneca has also stoked a dispute over supplies with former EU member Britain. AstraZeneca said it was prevented from exporting doses from UK factories to make up for some of the shortfalls in the EU, EU officials have said. Now the EU is opposing the export of AstraZeneca shots to Britain from a factory in the Netherlands.
Israel examines inflammation cases after Pfizer shot Israel is examining dozens of cases where people experienced heart inflammation after receiving Pfizer Inc. and BioNTechSE’s coronavirus vaccine. Health officials are investigating whether the cases are connected with the shot which has been administered to more than 5 million people, Corona Commissioner Nachman Ash said in an interview with Radio 103 FM.The government identified 62 incidents of inflammation of the heart muscle, or heart-muscle membrane, Channel 12 reported last week, citing a health ministry study.
Moderna to be reviewed for WHO emergency listing in April Moderna's Covid-19 vaccine will be reviewed on April 30 by technical experts for possible WHO emergency-use listing, a World Health Organization spokesman told Reuters. “We are discussing the Moderna Covid-19 vaccine on Friday...," WHO spokesman Christian Lindmeier said in reply to a query. A decision on the U. S. drugmaker's vaccine, now being evaluated under the abridged procedure on the basis of priorre view by the European Medicines Agency, was expected in one to four days after that, Lindmeier said. Astra’s vaccine designer seeks $613-million value in IPO The University of Oxford spin off that designed AstraZeneca’s Covid-19 vaccineis seeking a valuation as high as $613 million in its initial public offering in the US, a move to help fund trials for new directions in cancer and other diseases. Vaccitech is set to offer 6.5 million American depository shares for as much as $18 each and will be listed on the NSE, according to a filing. The company, which will trade under the VACC ticker, will use the proceeds to advance the development of vaccines for hepatitis B virus, human papilloma virus and prostate cancer. Thailand PM fined for not wearing face mask Thailand Prime Minister Gen. Prayut Chan-o-cha was fined 6,000 baht (Rs 14,270) on Monday for not wearing a mask, as his government struggled to combat a new wave of coronavirus cases in the country. Gen. Prayut was fined as he did not wear a mask during a meeting with his vaccine procurement advisers on Monday, the Bangkok Post reported. The Thai capital Bangkok has made mask-wearing compulsory from Monday. Thai officials are imposing fines of upto 20,000 baht (Rs 47,610) on people who fail to wear face masks in public.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU